RF GP Ablation Added to PEF PVI for Paroxysmal AF (REGATTA-AF)

November 11, 2026 updated by: Predrag Stojadinovic, Institute for Clinical and Experimental Medicine

RadiofrEquency Ablation of Ganglionated Plexi Added to The Pulsed ElecTric Field Pulmonary Vein Isolation for PAroxysmal Atrial Fibrillation (REGATTA-AF Study)

This study will investigate whether adjunctive RF GP ablation, when added to PF PVI, improves freedom from AF or atrial tachycardia (AT). By directly addressing the potential limitation of autonomic modulation associated with PF ablation alone, this study will provide mechanistic and clinically relevant insights into the role of parasympathetic modulation of the heart in preventing AF recurrence.

The results are expected to yield novel, clinically meaningful evidence that may help refine and optimize catheter ablation workflows, particularly in the era of non-thermal energy sources.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and pulmonary vein isolation (PVI) represents the cornerstone therapeutic strategy in patients with symptomatic paroxysmal AF. Pulsed electric field (PEF) ablation is a novel energy source that enables safe and durable PVI but has a limited and only transient effect on the autonomic nervous system, which plays an important role in the pathogenesis of AF. Previous studies have shown that modification of ganglionated plexi (GP) using radiofrequency (RF) energy may result in more effective and sustained parasympathetic atrial denervation, thereby potentially improving long-term ablation outcomes.

The aim of this project is to compare the efficacy of PEF PVI alone versus a combined strategy of PEF PVI plus adjunctive RF GP ablation in patients with antiarrhythmic drug-refractory paroxysmal AF. This is a multicentre, randomized, single-blind superiority trial. A total of 250 patients will be enrolled across three highly specialized centres in the Czech Republic. The primary endpoint is freedom from recurrent AF/atrial tachycardia lasting >30 seconds during 12 months of follow-up (excluding a 2-month blanking period) without the use of Class I/III antiarrhythmic drugs. Secondary endpoints include arrhythmia burden assessed by long-term ECG monitoring, quality of life, procedural safety, and detailed evaluation of cardiac autonomic function using both invasive and non-invasive methods.

The project will provide the first direct clinical evidence on the benefit of targeted autonomic modulation added to PEF PVI. The results may substantially influence the optimization of ablation strategies in paroxysmal AF and contribute to the refinement of future clinical guidelines.

Study Type

Interventional

Enrollment (Estimated)

250

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Prague
      • Prague, Prague, Czechia, 14200
        • Institute for Clinical and Experimental Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients with drug-resistant symptomatic paroxysmal AF meeting all the following criteria:

    1. Paroxysmal AF that terminates spontaneously or with intervention within 7 days of onset.
    2. Failed AAD treatment, defined as ineffective, intolerant or inappropriate ≥1 Class I-IV AAD.
  2. Patients who are ≥30 and ≤65 years of age on the day of enrolment.

  3. Patients who are willing and capable of:

    1. Providing informed consent to undergo study procedures AND
    2. Participating in all examinations, follow-up visits, and tests associated with this clinical study.
  4. Effective contraception for women of childbearing potential.

  5. Effective oral anticoagulation for >3 weeks before the planned ablation procedure.

Exclusion Criteria:

  1. Persistent, long-standing persistent, or permanent AF.
  2. AF secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
  3. Left atrial (LA) anteroposterior diameter ≥50 mm (by transthoracic echocardiography).
  4. Left ventricular ejection fraction <40%.
  5. Autonomic dysfunction, e.g., cardiac autonomic neuropathy due to diabetes mellitus.
  6. Any prior atrial endocardial or epicardial ablation procedure, including cavotricuspid isthmus (CTI) ablation or right-sided AT.
  7. Any prior atrial surgery.
  8. Intra-atrial septal patch or interatrial shunt.
  9. General contraindications of catheter ablation
  10. LA appendage closure, device, or occlusion, past or anticipated.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: RF GP + PEF PVI

Radiofrequency ablation of ganglionated plexi added to pulmonary vein isolation and roof line ablation using pulsed electric field

isolation of pulmonary veins and roof line ablation using pulsed electric energy

ablation of GP using radiofrequency energy

Active Comparator: PEF PVI

Pulmonary vein isolation and roof line ablation using pulsed electric field energy

isolation of pulmonary veins and roof line ablation using pulsed electric energy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Freedom from recurrent AF/AT >30 s during the first 12 months
Time Frame: From the ablation procedure through the 12-month follow-up.

The primary outcome of the study is freedom from recurrent AF/AT >30 s during the first 12 months (excluding a 2-month blanking period) after the procedure without the use of Class I or III AADs.

From the ablation procedure through the 12-month follow-up.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life
Time Frame: Baseline and at the 12-month visit.

This measure will be assessed by the AFEQT questionnaire. A higher score = a better quality of life (0 = worst possible quality of life, 50 = intermediate impairment, and 100 = best possible quality of life).

Baseline and at the 12-month visit.
Periprocedural complications, MACE
Time Frame: From the ablation procedure through the 12-month follow-up.

periprocedural complications, including cardiac tamponade, stroke/TIA, major bleeding requiring intervention or transfusion, vascular access complications requiring treatment; major adverse cardiac events during follow-up

From the ablation procedure through the 12-month follow-up.
Acute vagal denervation assessed by ECVS
Time Frame: Periprocedural

ECVS will be performed during the ablation procedure at baseline and 20 minutes after the last PF of RF application. The longest P-P and R-R pauses ( in seconds) during ECVS will be recorded.

Periprocedural
Long-term cardiac vagal denervation
Time Frame: Baseline and at the 12-month visit.

Patients will undergo atropine testing consisting of an intravenous bolus of atropine sulfate. ECG will be recorded immediately before and 5 minutes after the injection.

Baseline and at the 12-month visit.
Vagal atrial induction test (VAFIT)
Time Frame: Periprocedural

This test will be performed to assess the inducibility of AF/AF at baseline and at the end of the procedure. The induction protocol will use programmed atrial stimulation (a short train of 4 cycles at 120 bpm followed by one extrastimulus) from the low lateral right atrium, synchronised with the ECVS.

Periprocedural

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2027

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

April 1, 2029

Study Registration Dates

First Submitted

March 14, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IClinicalEM

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.